Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKG:1858)
12.26
+0.05 (0.41%)
Apr 29, 2026, 4:08 PM HKT
HKG:1858 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,045 | 805.22 | 1,207 | 1,199 | 1,107 | Upgrade
|
| Other Revenue | 0.8 | 0.64 | 1.04 | 2.58 | 0.91 | Upgrade
|
| Revenue | 1,046 | 805.86 | 1,209 | 1,202 | 1,108 | Upgrade
|
| Revenue Growth (YoY) | 29.77% | -33.32% | 0.58% | 8.43% | 18.18% | Upgrade
|
| Cost of Revenue | 392.37 | 289.37 | 353.34 | 301.53 | 264.11 | Upgrade
|
| Gross Profit | 653.4 | 516.49 | 855.18 | 900.08 | 844.03 | Upgrade
|
| Selling, General & Admin | 250.44 | 285.54 | 427.61 | 430.31 | 372.73 | Upgrade
|
| Research & Development | 118.5 | 133.1 | 157.45 | 162.34 | 104.84 | Upgrade
|
| Other Operating Expenses | 4.48 | 1.62 | 4.41 | 13.33 | 9.2 | Upgrade
|
| Operating Expenses | 383.13 | 424.53 | 593.88 | 618.73 | 499.58 | Upgrade
|
| Operating Income | 270.27 | 91.96 | 261.3 | 281.35 | 344.44 | Upgrade
|
| Interest Expense | -0.04 | -0.04 | -0.09 | -0.05 | - | Upgrade
|
| Interest & Investment Income | 21.59 | 27.29 | 26.47 | 23.6 | 10.76 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.68 | 1.78 | 2.48 | 3.57 | -0.86 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.16 | -0.9 | -0.18 | -4.27 | -4.22 | Upgrade
|
| EBT Excluding Unusual Items | 287.99 | 120.09 | 289.99 | 304.2 | 350.12 | Upgrade
|
| Impairment of Goodwill | - | -13.36 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.74 | 9.43 | 9.61 | 9.49 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0 | 0.04 | 0 | 0.03 | 0.01 | Upgrade
|
| Other Unusual Items | 4.98 | 15.39 | 6.3 | 23.16 | 17.24 | Upgrade
|
| Pretax Income | 301.71 | 131.6 | 305.91 | 336.88 | 367.38 | Upgrade
|
| Income Tax Expense | 29.09 | 6.94 | 28.09 | 29.16 | 45.02 | Upgrade
|
| Earnings From Continuing Operations | 272.63 | 124.66 | 277.82 | 307.72 | 322.36 | Upgrade
|
| Minority Interest in Earnings | -0.08 | 0.33 | 0.01 | - | - | Upgrade
|
| Net Income | 272.54 | 124.99 | 277.82 | 307.72 | 322.36 | Upgrade
|
| Net Income to Common | 272.54 | 124.99 | 277.82 | 307.72 | 322.36 | Upgrade
|
| Net Income Growth | 118.05% | -55.01% | -9.71% | -4.54% | 13.76% | Upgrade
|
| Shares Outstanding (Basic) | 384 | 379 | 386 | 385 | 347 | Upgrade
|
| Shares Outstanding (Diluted) | 384 | 379 | 386 | 385 | 347 | Upgrade
|
| Shares Change (YoY) | 1.35% | -1.84% | 0.32% | 10.97% | 0.30% | Upgrade
|
| EPS (Basic) | 0.71 | 0.33 | 0.72 | 0.80 | 0.93 | Upgrade
|
| EPS (Diluted) | 0.71 | 0.33 | 0.72 | 0.80 | 0.93 | Upgrade
|
| EPS Growth | 115.15% | -54.17% | -10.00% | -13.98% | 13.41% | Upgrade
|
| Free Cash Flow | 345.71 | -51.07 | 478.47 | 16.1 | -34.62 | Upgrade
|
| Free Cash Flow Per Share | 0.90 | -0.14 | 1.24 | 0.04 | -0.10 | Upgrade
|
| Dividend Per Share | 0.360 | 0.132 | 0.362 | 0.313 | 0.130 | Upgrade
|
| Dividend Growth | 172.73% | -63.54% | 15.65% | 140.77% | - | Upgrade
|
| Gross Margin | 62.48% | 64.09% | 70.76% | 74.91% | 76.17% | Upgrade
|
| Operating Margin | 25.84% | 11.41% | 21.62% | 23.41% | 31.08% | Upgrade
|
| Profit Margin | 26.06% | 15.51% | 22.99% | 25.61% | 29.09% | Upgrade
|
| Free Cash Flow Margin | 33.06% | -6.34% | 39.59% | 1.34% | -3.12% | Upgrade
|
| EBITDA | 309.43 | 128.84 | 294.55 | 309.48 | 360.99 | Upgrade
|
| EBITDA Margin | 29.59% | 15.99% | 24.37% | 25.75% | 32.58% | Upgrade
|
| D&A For EBITDA | 39.16 | 36.88 | 33.25 | 28.13 | 16.55 | Upgrade
|
| EBIT | 270.27 | 91.96 | 261.3 | 281.35 | 344.44 | Upgrade
|
| EBIT Margin | 25.84% | 11.41% | 21.62% | 23.41% | 31.08% | Upgrade
|
| Effective Tax Rate | 9.64% | 5.27% | 9.18% | 8.66% | 12.25% | Upgrade
|
| Revenue as Reported | 1,046 | 805.86 | 1,209 | 1,202 | 1,108 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.